Over-expression of nerve growth factor-β in human cholangiocarcinoma QBC939 cells promote tumor progression

PLoS One. 2013 Apr 24;8(4):e62024. doi: 10.1371/journal.pone.0062024. Print 2013.

Abstract

Aims: It has been shown that nerve growth factor-β (NGF-β) promoted the initiation and progression of many tumors, and we have previously demonstrated that the expression of NGF-β was associated with tumor stage, nerve infiltration and lymph node metastasis in human hilar cholangiocarcinoma. However, whether NGF-β promotes tumor progression in human cholangiocarcinoma requires further investigation. Therefore, we aimed to determine the effects of NGF-β on the progression of human cholangiocarcinoma.

Methods: Human cholangiocarcinoma QBC939 stable cell lines with over-expressed or silenced NGF-β genes were generated with pEGFP-N1-NGF-β and pGPU6/GFP/Neo-NGF-β-shRNA recombinant plasmids. Cell proliferation assay, colony formation assay, cell cycle analysis, apoptosis assay and tumorigenicity assay were performed to evaluate the role of NGF-β in the progression of human cholangiocarcinoma. In addition, human lymphatic endothelial cells were co-cultured with QBC939 culture supernatants, and the cell proliferation and migration abilities of the lymphatic endothelial cells were evaluated.

Results: Forced expression of NGF-β in QBC939 cell lines promoted proliferation, colony formation and tumorigenicity in these cells and inhibited the apoptosis. However, down-regulation of NGF-β inhibited proliferation, colony formation and tumorigenicity, and increased the apoptotic rate of QBC939 cells. In addition, the NGF-β gain-of-function induced a high expression of vascular endothelial growth factor C and enhanced the proliferation and migration of lymphatic endothelial cells, while NGF-β loss-of-function showed opposite effects.

Conclusions: We concluded that NGF-β promoted tumor progression in human cholangiocarcinoma QBC939 cells. Our results provided a new concept to understand the role of NGF-β in cholangiocarcinoma progression, and might provide important information for the development of new targeted therapies in human cholangiocarcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Cell Cycle / genetics
  • Cell Line, Tumor
  • Cell Movement / genetics
  • Cell Proliferation
  • Cell Transformation, Neoplastic / genetics
  • Cholangiocarcinoma / genetics*
  • Cholangiocarcinoma / pathology*
  • Disease Progression
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Expression*
  • Gene Order
  • Gene Silencing
  • Heterografts
  • Humans
  • Mice
  • Nerve Growth Factor / genetics*
  • Tumor Burden / genetics
  • Vascular Endothelial Growth Factor C / genetics

Substances

  • Vascular Endothelial Growth Factor C
  • Nerve Growth Factor

Grants and funding

This work was supported by The Special Research Foundation of the National Nature Science Foundation of China (81172068). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.